Art. 75 Regulation (EU) 2017/745

Substantial modifications to clinical investigations

In forcesince 5 Apr 2017cited 6×
1.

If a sponsor intends to introduce modifications to a clinical investigation that are likely to have a substantial impact on the safety, health or rights of the subjects or on the robustness or reliability of the clinical data generated by the investigation, it shall notify, within one week, by means of the electronic system referred to in Article 73 the Member State(s) in which the clinical investigation is being or is to be conducted of the reasons for and the nature of those modifications. The sponsor shall include an updated version of the relevant documentation referred to in Chapter II of Annex XV as part of the notification. Changes to the relevant documentation shall be clearly identifiable.

2.

The Member State shall assess any substantial modification to the clinical investigation in accordance with the procedure laid down in Article 71.

3.

The sponsor may implement the modifications referred to in paragraph 1 at the earliest 38 days after the notification referred to in that paragraph, unless:

(a)

the Member State in which the clinical investigation is being or is to be conducted has notified the sponsor of its refusal based on the grounds referred to in Article 71(4) or on considerations of public health, subject and user safety or health, of public policy, or

(b)

an ethics committee in that Member State has issued a negative opinion in relation to the substantial modification to the clinical investigation, which, in accordance with national law, is valid for that entire Member State.

4.

The Member State(s) concerned may extend the period referred to in paragraph 3 by a further seven days, for the purpose of consulting with experts.

  • MPDG40414285Law

    … in geeigneter Form den unverzüglichen Zugang zu der Mitteilung des Sponsors über eine wesentliche Änderung nach Artikel 75 der Verordnung (EU) 2017/745 oder Artikel 71 der Verordnung (EU) 2017/746.

  • Code de la santé publiquer1125-11r1125-4Law

    … Ces demandes sont accompagnées des justifications appropriées dans les conditions prévues par le 1 de l'article 75 du règlement (UE) 2017/745 du 5 avril 2017. Le promoteur informe le comité et, le cas échéant, l'autorité précitée …

  • Medizinproduktegesetz 202124Law

    § 24. Die §§ 18 bis 23 gelten auch für wesentliche Änderungen von klinischen Prüfungen gemäß Art. 75 der Verordnung (EU) Nr. 745/2017 oder einer Leistungsstudie gemäß Art. 71 der Verordnung (EU) Nr. 746/2017.

  • BMGBGebVLaw

  • BMGBGebVLaw

    … (MPDG) | 2 000 bis 9 900 2.2 | Prüfung einer wesentlichen Änderung an einer klinischen Prüfung nach Artikel 75 der Verordnung (EU) 2017/745 | 600 bis 2 000 2.3 | Prüfung einer Mitteilung des Sponsors bei vorübergehender Aussetzung …

  • MPDG40414285Law